{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:01:53Z","timestamp":1790913713468,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.clml.2016.02.040","type":"journal-article","created":{"date-parts":[[2016,3,3]],"date-time":"2016-03-03T03:22:07Z","timestamp":1456975327000},"page":"366-371.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib"],"prefix":"10.1016","volume":"16","author":[{"given":"Radhika","family":"Unnikrishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendran","family":"Veeraiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samson","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rejiv","family":"Rajendranath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swaminathan","family":"Rajaraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Sahaya","family":"Vidhubala Elangovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatraman","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trivadi S.","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenali G.","family":"Sagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanth","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.02.040_bib1","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","article-title":"How I treat chronic myeloid leukemia in the imatinib era","volume":"110","author":"Goldman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.040_bib2","first-page":"56","article-title":"Patient adherence and persistence with oral anticancer treatment","volume":"59","author":"Ruddy","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2016.02.040_bib3","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/94.9.652","article-title":"Adherence to therapy with oral antineoplastic agents","volume":"94","author":"Partridge","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2016.02.040_bib4","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.02.040_bib5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2012.082511","article-title":"Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges","volume":"99","author":"Noens","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.02.040_bib6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ajh.22019","article-title":"Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia","volume":"86","author":"Ganesan","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2016.02.040_bib7","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.040_bib8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia","volume":"25","author":"Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clml.2016.02.040_bib9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.clml.2012.04.002","article-title":"Adherence to BCR-ABL inhibitors: issues for CML therapy","volume":"12","author":"Jabbour","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2016.02.040_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4103\/0971-5851.123700","article-title":"Chronic myeloid leukemia in India","volume":"34","author":"Goldman","year":"2013","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.clml.2016.02.040_bib11","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4103\/0971-5851.123716","article-title":"Report of chronic myeloid leukemia in chronic phase from Tata Memorial Hospital, Mumbai, 2002-2008","volume":"34","author":"Parikh","year":"2013","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.clml.2016.02.040_bib12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","article-title":"Predictive validity of a medication adherence measure in an outpatient setting","volume":"10","author":"Morisky","year":"2008","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.clml.2016.02.040_bib13","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2147\/PPA.S70712","article-title":"Chronic myeloid leukemia patients\u2019 adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians","volume":"8","author":"Kek\u00e4le","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clml.2016.02.040_bib14","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/bjc.2012.348","article-title":"Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study","volume":"107","author":"Efficace","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2016.02.040_bib15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s11136-013-0523-5","article-title":"International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24","volume":"23","author":"Efficace","year":"2014","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clml.2016.02.040_bib16","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.02.040_bib17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3324\/haematol.2013.094045","article-title":"Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden","volume":"99","author":"Baccarani","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.02.040_bib18","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4103\/2279-042X.128145","article-title":"Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea","volume":"2","author":"Jain","year":"2013","journal-title":"J\u00a0Res Pharm Pract"},{"key":"10.1016\/j.clml.2016.02.040_bib19","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2016.02.040_bib20","first-page":"189","article-title":"The challenge of patient adherence","volume":"1","author":"Martin","year":"2005","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clml.2016.02.040_bib21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2016.02.040_bib22","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/leu.2013.51","article-title":"Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib","volume":"27","author":"Efficace","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2016.02.040_bib23","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s12032-011-9926-8","article-title":"Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients","volume":"29","author":"Moon","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2016.02.040_bib24","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016001002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016001002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:50Z","timestamp":1761870470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016001002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S2152265016001002"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.02.040","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.02.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}